Tags

Type your tag names separated by a space and hit enter

Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
J Am Soc Nephrol. 2006 Dec; 17(12 Suppl 3):S231-5.JA

Abstract

Although substantial evidence suggests that treatment of dyslipidemia with statins reduces mortality and morbidity that are associated with cardiovascular disease, only a few studies have examined the efficacy of statins on inflammatory and fibrinolytic status in patients with chronic kidney disease (CKD). A 6-mo, prospective, randomized study was designed to assess the efficacy of atorvastatin in reducing circulating inflammatory and fibrinolytic parameters in patients with CKD. Sixty-six patients with CKD (stages 2, 3, and 4) and LDL cholesterol levels > or =100 mg/dl were randomly assigned (2:1) to receive 20 mg/d atorvastatin (n = 44) or nonatorvastatin therapy (n = 22). Lipid profile, renal function, fibrinolytic balance (tissue plasminogen activator [t-PA] and plasminogen activator inhibitor-1), and inflammatory markers (C-reactive protein [CRP], IL-1 beta, IL-6, and TNF-alpha) were measured before and 6 mo after atorvastatin was added to the treatment. Twenty-five age-matched individuals with normal renal function (estimated GFR >90 ml/min) were used as healthy control subjects. Patients with CKD had higher CRP, IL-1 beta, TNF-alpha, and IL-6 levels than age-matched population with normal renal function. t-PA concentration was higher in patients with CKD (P = 0.000). Plasminogen activator inhibitor-1 values were comparable in all patients. Total cholesterol and LDL cholesterol were significantly reduced only in patients who received atorvastatin. In addition to the hypolipidemic effect, atorvastatin treatment significantly reduced inflammatory parameters: CRP (median 4.1 to 2.9; P = 0.015), TNF-alpha (6.0 +/- 2.7 to 4.7 +/- 2.4; P = 0.046), and IL-1 beta levels (1.9 +/- 0.7 to 1.2 +/- 0.7; P = 0.001). These parameters remained unchanged in patients who were not treated with atorvastatin. Fibrinolytic parameters were not modified by atorvastatin treatment. Patients with CKD showed higher levels of inflammatory parameters and t-PA levels than age-matched healthy control subjects. Atorvastatin treatment, in addition to its beneficial effect on cholesterol levels, improved the inflammatory state of these patients without modifying fibrinolytic balance.

Links

FREE Publisher Full Text

Authors+Show Affiliations

Goicoechea M
Department of Nephrology, Hospital General Universitario Gregorio Marañon, C/Dr. Esquerdo 47, 28007 Madrid, Spain. albvia@terra.es
de Vinuesa SG
No affiliation info available
Lahera V
No affiliation info available
Cachofeiro V
No affiliation info available
Gómez-Campderá F
No affiliation info available
Vega A
No affiliation info available
Abad S
No affiliation info available
Luño J
No affiliation info available

MeSH

AgedAged, 80 and overAtorvastatinC-Reactive ProteinCardiovascular DiseasesChronic DiseaseDose-Response Relationship, DrugDyslipidemiasFemaleFibrinogenFibrinolysisHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationInterleukin-6Kidney DiseasesLipid MetabolismMaleMiddle AgedPlasminogen Activator Inhibitor 1Prospective StudiesPyrrolesTissue Plasminogen Activator

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17130267

Citation

Goicoechea, Marian, et al. "Effects of Atorvastatin On Inflammatory and Fibrinolytic Parameters in Patients With Chronic Kidney Disease." Journal of the American Society of Nephrology : JASN, vol. 17, no. 12 Suppl 3, 2006, pp. S231-5.
Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(12 Suppl 3):S231-5.
Goicoechea, M., de Vinuesa, S. G., Lahera, V., Cachofeiro, V., Gómez-Campderá, F., Vega, A., Abad, S., & Luño, J. (2006). Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology : JASN, 17(12 Suppl 3), S231-5.
Goicoechea M, et al. Effects of Atorvastatin On Inflammatory and Fibrinolytic Parameters in Patients With Chronic Kidney Disease. J Am Soc Nephrol. 2006;17(12 Suppl 3):S231-5. PubMed PMID: 17130267.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. AU - Goicoechea,Marian, AU - de Vinuesa,Soledad García, AU - Lahera,Vicente, AU - Cachofeiro,Victoria, AU - Gómez-Campderá,Francisco, AU - Vega,Almudena, AU - Abad,Soraya, AU - Luño,José, PY - 2006/11/30/pubmed PY - 2007/12/12/medline PY - 2006/11/30/entrez SP - S231 EP - 5 JF - Journal of the American Society of Nephrology : JASN JO - J Am Soc Nephrol VL - 17 IS - 12 Suppl 3 N2 - Although substantial evidence suggests that treatment of dyslipidemia with statins reduces mortality and morbidity that are associated with cardiovascular disease, only a few studies have examined the efficacy of statins on inflammatory and fibrinolytic status in patients with chronic kidney disease (CKD). A 6-mo, prospective, randomized study was designed to assess the efficacy of atorvastatin in reducing circulating inflammatory and fibrinolytic parameters in patients with CKD. Sixty-six patients with CKD (stages 2, 3, and 4) and LDL cholesterol levels > or =100 mg/dl were randomly assigned (2:1) to receive 20 mg/d atorvastatin (n = 44) or nonatorvastatin therapy (n = 22). Lipid profile, renal function, fibrinolytic balance (tissue plasminogen activator [t-PA] and plasminogen activator inhibitor-1), and inflammatory markers (C-reactive protein [CRP], IL-1 beta, IL-6, and TNF-alpha) were measured before and 6 mo after atorvastatin was added to the treatment. Twenty-five age-matched individuals with normal renal function (estimated GFR >90 ml/min) were used as healthy control subjects. Patients with CKD had higher CRP, IL-1 beta, TNF-alpha, and IL-6 levels than age-matched population with normal renal function. t-PA concentration was higher in patients with CKD (P = 0.000). Plasminogen activator inhibitor-1 values were comparable in all patients. Total cholesterol and LDL cholesterol were significantly reduced only in patients who received atorvastatin. In addition to the hypolipidemic effect, atorvastatin treatment significantly reduced inflammatory parameters: CRP (median 4.1 to 2.9; P = 0.015), TNF-alpha (6.0 +/- 2.7 to 4.7 +/- 2.4; P = 0.046), and IL-1 beta levels (1.9 +/- 0.7 to 1.2 +/- 0.7; P = 0.001). These parameters remained unchanged in patients who were not treated with atorvastatin. Fibrinolytic parameters were not modified by atorvastatin treatment. Patients with CKD showed higher levels of inflammatory parameters and t-PA levels than age-matched healthy control subjects. Atorvastatin treatment, in addition to its beneficial effect on cholesterol levels, improved the inflammatory state of these patients without modifying fibrinolytic balance. SN - 1046-6673 UR - https://www.unboundmedicine.com/medline/citation/17130267/Effects_of_atorvastatin_on_inflammatory_and_fibrinolytic_parameters_in_patients_with_chronic_kidney_disease_ L2 - https://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17130267 DB - PRIME DP - Unbound Medicine ER -